Latest On Nemaura Medical Inc (NMRD):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-09 20:13 EST | News | Nemaura Medical regains Nasdaq listing compliance | N/A |  |
| 2023-02-24 20:38 EST | News | Nemaura Medical GAAP EPS of -$0.07, revenue of $0.03M | N/A | |
| 2023-01-27 11:29 EST | News | Nemaura Medical stock dips after pricing ~$8.4M securities offering | N/A | |
| 2023-01-24 17:59 EST | News | Nemaura says all patients in Miboko health program achieved weight loss | N/A | |
| 2022-11-15 22:49 EST | News | Nemaura Medical GAAP EPS of -$0.17 in-line, revenue of $0.07M misses by $0.06M | N/A | |
| 2022-08-22 02:30 EST | News | Nemaura Medical (NMRD) Investor Presentation - Slideshow | N/A | |
| 2022-08-15 19:24 EST | News | Nemaura Medical GAAP EPS of -$0.17 | N/A | |
| 2022-06-30 14:48 EST | News | Nemaura Medical GAAP EPS of -$0.59 misses by $0.12, revenue of $0.51M | N/A | |
| 2022-05-24 01:30 EST | News | Nemaura Medical secures $5M in non-dilutive funding | N/A | |
| 2022-03-30 05:04 EST | News | Nemaura Medical attracts Bull rating from HC Wainwright on glucose monitoring tech | N/A | |
| 2022-03-10 19:39 EST | News | Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market | N/A | |
| 2022-02-14 11:54 EST | News | Nemaura Medical GAAP EPS of -$0.15, revenue of $0.18M | N/A | |
| 2021-11-16 05:17 EST | News | Nemaura Medical EPS misses by $0.04 | N/A | |
| 2021-10-27 23:08 EST | News | Warning: NMRD is at high risk of performing badly | N/A | |
| 2021-10-06 13:57 EST | News | NMRD is at high risk of performing badly | N/A | |
| 2021-09-27 22:58 EST | News | Warning: NMRD has been downgraded to Very Bearish | N/A | |
| 2021-09-27 22:44 EST | News | Nemaura Medical in pact with MySugarWatch for glucose monitors | N/A | |
| 2021-09-23 08:43 EST | News | Warning: NMRD has been downgraded to Very Bearish. | N/A | |
| 2021-09-22 01:59 EST | News | Nemaura Medical: From Believer To Skeptic | N/A | |
| 2021-08-16 22:14 EST | News | Nemaura Medical EPS misses by $0.06 | N/A | |
| 2021-07-21 17:15 EST | News | Nemaura Medical EPS beats by $0.02 | N/A | |
| 2021-07-21 17:11 EST | News | Nemaura: Wearable Monitoring Patches For Type-2 Diabetics Could Be An Inspired Move | N/A | |
| 2021-05-06 16:28 EST | News | Nemaura Medical rallies on listing of sugarBEAT for reimbursement in Germany | N/A | |
| 2021-05-05 20:29 EST | News | Nemaura Medical rallies on 200K sugarBEAT sensors order | N/A | |
| 2021-02-22 00:07 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $15. | Buy | |
| 2021-02-16 13:25 EST | News | Nemaura Medical reports Q3 results | N/A | |
| 2021-02-14 00:13 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-10 15:55 EST | News | Nemaura Medical rises 67% in premarket | N/A | |
| 2021-02-10 15:55 EST | News | Nemaura Medical's SugarBEAT: A Rising Star In Continuous Glucose Monitoring | N/A | |
| 2021-02-10 15:55 EST | News | Zomedica, Nemaura and Senseonics extend premarket gains | N/A | |
| 2021-02-03 23:09 EST | News | Nemaura Medical: Lowering Glucose Levels Will Increase Share Price | N/A | |
| 2020-11-26 20:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-18 04:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 00:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 16:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 13:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-18 12:46 EST | News | Nemaura Medical names new CFO | N/A | |
| 2020-09-17 05:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-05 09:53 EST | News | Nemaura Medical (NMRD) Investor Presentation - Slideshow | N/A | |
| 2020-08-17 10:39 EST | News | Nemaura Medical reports Q1 results | N/A | |
| 2020-08-16 01:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 09:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 21:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 13:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 01:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 02:29 EST | News | Nemaura poised to acquire diabetes prevention app developer | N/A | |
| 2020-07-28 02:28 EST | News | Nemaura to initiate equity offering | N/A | |
| 2020-07-27 13:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-24 07:47 EST | News | Nemaura Medical to integrate third party activity data into glucose monitor | N/A | |
About Nemaura Medical Inc (NMRD):
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
General
- Name Nemaura Medical Inc
- Symbol NMRD
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Devices
- Full Time Employees 17
- Last Split Factor1:10
- Last Split Date2019-12-05
- Fiscal Year EndMarch
- IPO Date2016-03-04
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Gic SubIndustryHealth Care Equipment
- Web URLhttp://nemauramedical.com
View More
Valuation
- Price/Book (Most Recent Quarter) 17.87
View More
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -29%
- Return on Equity -108%
- Earnings Per Share -$0.02
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 181.15 million
- EBITDA -4922273
- Analyst Target Price $15
- Book Value Per Share $0.45
View More
Share Statistics
- Shares Outstanding 22.93 million
- Shares Float 8.8 million
- % Held by Insiders 6169%
- % Held by Institutions 6.67%
- Shares Short 363786
- Shares Short Prior Month 275775
- Short Ratio 0.72
- Short % of Float 4%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta -0.17
- 52 Week High $16.5
- 52 Week Low $3.12
- 50 Day Moving Average 7.28
- 200 Day Moving Average 4.79
View More
Dividends
- Dividend Date 2019-12-05
- ExDividend Date N/A
- Dividend Yield 0%
View More
Nemaura Medical Inc (NMRD) Dividend Calendar:
NMRD's last dividend payment was made to shareholders on December 5, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Nemaura Medical Inc (NMRD) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-03 | $N/A | -$0.06 | ||
| 2020-09-30 | 2020-11-13 | $N/A | -$0.07 | ||
| 2020-06-30 | 2020-08-14 | $N/A | -$0.05 | ||
| 2020-03-31 | 2020-06-30 | $N/A | -$0.06 | -$0.07 | 14.29% |
| 2019-12-31 | 2020-02-10 | $N/A | -$0.02 | -$0.10 | 80% |
| 2019-09-30 | 2019-11-08 | $N/A | -$0.10 | -$0.10 | 0% |
| 2019-06-30 | 2019-08-09 | $N/A | -$0.10 | -$0.10 | 0% |
| 2019-03-31 | 2019-06-14 | $N/A | -$0.08 | ||
| 2018-12-31 | 2019-02-12 | $N/A | -$0.05 | ||
| 2018-09-30 | 2018-11-06 | $N/A | -$0.06 | ||
| 2018-06-30 | 2018-08-09 | $N/A | -$0.07 | ||
| 2018-03-31 | 2018-03-31 | $N/A | -$0.04 | ||
| 2017-12-31 | 2017-12-31 | $N/A | -$0.04 | ||
| 2017-09-30 | 2017-09-30 | $N/A | -$0.02 | ||
| 2017-06-30 | 2017-06-30 | $N/A | -$0.02 | ||
| 2017-03-31 | 2017-03-31 | $N/A | -$0.02 | ||
| 2016-12-31 | 2016-12-31 | $N/A | -$0.02 | ||
| 2016-09-30 | 2016-09-30 | $N/A | -$0.02 | ||
| 2016-06-30 | 2016-06-30 | $N/A | -$0.02 | ||
| 2016-03-31 | 2016-03-31 | $N/A | -$0.02 | ||
| 2015-12-31 | 2015-12-31 | $N/A | -$0.02 | ||
| 2015-09-30 | 2015-09-30 | $N/A | -$0.02 | ||
| 2015-06-30 | 2015-06-30 | $N/A | -$0.02 | ||
| 2015-03-31 | 2015-03-31 | $N/A | -$0.03 | ||
| 2014-12-31 | 2014-12-31 | $N/A | -$0.01 |
Nemaura Medical Inc (NMRD) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Nemaura Medical Inc (NMRD) Chart:
Nemaura Medical Inc (NMRD) News:
Below you will find a list of latest news for Nemaura Medical Inc (NMRD) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Nemaura Medical Inc (NMRD) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Nemaura Medical Inc (NMRD) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000568/0001079973-20-000568-index.htm |
| 2019-04-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1602078/000000000019006544/0000000000-19-006544-index.htm |
| 2018-12-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997318000695/0001079973-18-000695-index.htm |
| 2019-02-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000062/0001079973-19-000062-index.htm |
| 2019-02-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000071/0001079973-19-000071-index.htm |
| 2019-02-12 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000079/0001079973-19-000079-index.htm |
| 2019-03-27 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000185/0001079973-19-000185-index.htm |
| 2019-03-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000186/0001079973-19-000186-index.htm |
| 2019-04-04 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000203/0001079973-19-000203-index.htm |
| 2019-04-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000212/0001079973-19-000212-index.htm |
| 2019-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000224/0001079973-19-000224-index.htm |
| 2019-04-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000230/0001079973-19-000230-index.htm |
| 2019-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000236/0001079973-19-000236-index.htm |
| 2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000331/0001079973-19-000331-index.htm |
| 2019-06-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000357/0001079973-19-000357-index.htm |
| 2019-07-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000389/0001079973-19-000389-index.htm |
| 2019-07-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000414/0001079973-19-000414-index.htm |
| 2019-08-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000429/0001079973-19-000429-index.htm |
| 2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000444/0001079973-19-000444-index.htm |
| 2019-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000453/0001079973-19-000453-index.htm |
| 2019-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000455/0001079973-19-000455-index.htm |
| 2019-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000514/0001079973-19-000514-index.htm |
| 2019-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000567/0001079973-19-000567-index.htm |
| 2019-12-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000621/0001079973-19-000621-index.htm |
| 2019-12-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997319000661/0001079973-19-000661-index.htm |
| 2020-02-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000094/0001079973-20-000094-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000128/0001079973-20-000128-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000144/0001079973-20-000144-index.htm |
| 2020-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000154/0001079973-20-000154-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000156/0001079973-20-000156-index.htm |
| 2020-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000191/0001079973-20-000191-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000232/0001079973-20-000232-index.htm |
| 2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000250/0001079973-20-000250-index.htm |
| 2020-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000258/0001079973-20-000258-index.htm |
| 2020-04-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000271/0001079973-20-000271-index.htm |
| 2020-04-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000305/0001079973-20-000305-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000336/0001079973-20-000336-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000372/0001079973-20-000372-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000409/0001079973-20-000409-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000431/0001079973-20-000431-index.htm |
| 2020-06-30 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000564/0001079973-20-000564-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000568/0001079973-20-000568-index.htm |
| 2020-07-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000578/0001079973-20-000578-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000592/0001079973-20-000592-index.htm |
| 2020-07-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000616/0001079973-20-000616-index.htm |
| 2020-07-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000621/0001079973-20-000621-index.htm |
| 2020-07-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000626/0001079973-20-000626-index.htm |
| 2020-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000632/0001079973-20-000632-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000651/0001079973-20-000651-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000697/0001079973-20-000697-index.htm |
| 2020-08-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000725/0001079973-20-000725-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000784/0001079973-20-000784-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000798/0001079973-20-000798-index.htm |
| 2020-11-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1602078/000107997320000911/0001079973-20-000911-index.htm |
| 2019-04-08 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1602078/999999999519000641/9999999995-19-000641-index.htm |